|
J Biol Chem, Vol. 273, Issue 34, 21648-21657, August 21, 1998
Comparative Properties of Two Cysteine Proteinases
(Gingipains R), the Products of Two Related but Individual Genes of
Porphyromonas gingivalis*
Jan
Potempa §,
Jowita
Mikolajczyk-Pawlinska ,
David
Brassell¶,
Daniel
Nelson¶,
Ida B.
Thøgersen ,
Jan J.
Enghild , and
James
Travis¶
From the Department of Microbiology and Immunology,
Institute of Molecular Biology, Jagiellonian University, 31-120 Kraków, Poland, the Department of Pathology, Duke
University Medical Center, Durham, North Carolina 27710, and the
¶ Department of Biochemistry and Molecular Biology, University of
Georgia, Athens, Georgia 30602
 |
ABSTRACT |
Proteolytic enzymes produced by
Porphyromonas gingivalis are important virulence factors of
this periodontopathogen. Two of these enzymes, referred to as
arginine-specific cysteine proteinases (gingipains R), are the product
of two related genes. Here, we describe the purification of an enzyme
translated from the rgpB/rgp-2 gene (gingipain R2, RGP-2)
and secreted as a single chain protein of 422 residues. The enzyme
occurs in several isoforms differing in pI, molecular mass, mobility in
gelatin zymography gels, and affinity to arginine-Sepharose. In
comparison to the 95-kDa gingipain R1, a complex of catalytic and
hemagglutinin/adhesin domains, RGP-2 showed five times lower
proteolytic activity, although its activity on various
P1-arginine p-nitroanilide substrates was generally higher. Gingipains R amidolytic activity, but not general proteolytic activity, was stimulated by glycyl-glycine. However, in
cases of limited proteolysis, such as the inactivation of
-1-antichymotrypsin, glycyl-glycine potentiated inhibitor cleavage.
In contrast, -1-proteinase inhibitor was not inactivated by
gingipains R and only underwent proteolytic degradation during boiling
in reducing SDS-polyacrylamide gel electrophoresis treatment buffer.
Similarly, native type I collagen was completely resistant to cleavage
by gingipains but readily degraded after denaturation. Together, these
data explain much of the controversy regarding gingipains structure and
substrate specificity and indicate that these enzymes function as
P. gingivalis virulence factors by proteolysis of selected
target proteins rather than random degradation of host connective
tissue components.
 |
INTRODUCTION |
Periodontal disease, the major cause of tooth loss in the general
population of industrial nations (1, 2), is a chronic inflammatory
disorder of tissues directly supporting the root of the tooth in
alveolar bone sockets. The disease is characterized by bone resorption,
loss of tooth attachment, and formation of periodontal pockets infested
with specific bacteria (3). Although more than 400 distinct bacterial
taxa have been identified in dental plaque samples, very few can be
correlated with the development and/or progression of the specific
clinical variants of periodontitis (2). Adult onset disease, the most
common form of periodontitis, is strongly associated with infections by
Porphyromonas gingivalis (4), and this is further
substantiated by the finding that infection by this bacterium initiates
periodontitis in primates (5) and can be avoided by animal immunization
with P. gingivalis antigens (6).
P. gingivalis, a Gram-negative, anaerobic, nonmotile,
nonsporing short rod elaborates a multiplicity of virulence factors involved in invasion, tissue destruction, and evasion of host defenses,
all of which enable this bacterium to colonize within its ecological
niche of either the gingival sulcus or periodontal pocket (reviewed in
Ref. 7). Among these factors, the primary focus of research has been on
proteolytic enzymes that are produced in large quantities by this
bacterium and could add to its pathogenicity. Indeed, it was shown that
these proteinases can directly or indirectly degrade constituents of
the periodontal tissues, destroy host defense elements, dysregulate
coagulation, complement, and kallikrein-kinin cascades. Thus, they
could be responsible for most of the clinical hallmarks of
periodontitis (reviewed in Ref. 8). Until recently, proteinases
belonging to two catalytic classes and produced by P. gingivalis have been identified. A serine proteinase with prolyl peptidase activity was found to be associated with the bacterial cell
surface (9), whereas large amounts of cysteine proteinases with
trypsin-like activity were detected in either a soluble form in culture
media or combined with whole bacteria or their membranous fragments,
including vesicles (10).
Because of convenient assay systems with chromogenic substrates,
trypsin-like enzymes were targets for numerous attempts at purification, but only recently has it become apparent that two distinct proteinases are responsible for this activity. One enzyme, described as an Arg-X specific proteinase, was purified from the culture media of P. gingivalis HG66, either as a single
chain 50-kDa proteinase
(RGP-1)1 (11) or a high
molecular mass (95 kDa) complex of a 50-kDa catalytic domain with
hemagglutinins/adhesins (12). Recently, molecular cloning and
characterization of its gene revealed that all components of the 95-kDa
gingipain-R (HRGP) are created by proteolytic processing of a single
polyprotein (13). Similarly, a Lys-X specific proteinase (gingipain K,
KGP) was separated as a 105-kDa protein complex composed of a unique
catalytic domain (60 kDa) associated with hemagglutinins/adhesins (12).
Since the first purified enzyme shared some properties with
clostripain, it was named as a gingipain (P. gingivalis clostripain) so that, following recommendations by the IUB, these proteinases are
referred to as gingipain-R and gingipain-K to account for their unique
specificity.
The construction of isogenic P. gingivalis mutants deficient
in the gingipain-R gene has shown unequivocally that these enzymes are
pivotal virulence factors (14) and, therefore, a perfect target for the
development of specific potentially therapeutic inhibitors. However,
before such compounds can be designed and tested as alternative
treatments to reduce adult periodontitis, the biochemical
characterization of rigorously purified gingipain-R forms is absolutely
necessary. In this report, we examine distinct forms of this enzyme
that have been found to be products of closely related but discrete
genes. In addition, we clarify a controversy regarding: (i) putative
collagenolytic activity, (ii) synthetic substrate specificity, (iii)
inhibition by plasma proteinase inhibitors, and iv)
stimulation of activity by glycyl-glycine.
 |
EXPERIMENTAL PROCEDURES |
Materials
Bz-L-Arg-pNA and tosyl-L-lysine
chloromethyl ketone were purchased from Sigma. S-2238
(D-Phe-Pip-Arg-pNA), S-2288
(D-Ile-Pro-Arg-pNA), S-2366 (pyroGlu-Pro-Arg-pNA), and
S-2444 (pyroGlu-Gly-Arg-pNA) were obtained from Pharmacia-Harper.
Z-Arg-pNA, Gly-Arg-pNA, Z-Arg-Arg-pNA, Z-Lys-Arg-pNA, Z-Phe-Arg-pNA,
Z-Tyr-Lys-Arg-pNA, Boc-Val-Leu-Gly-Arg-pNA, and Leu-Thr-Arg-pNA were
the product of Bachem. Chromozym TRY (Z-Val-Gly-Arg-pNA), Chromozym U
(Bz-Ala-Gly-Arg-pNA), Chromozym t-PA (MeS-Phe-Gly-Arg-pNA), Chromozym
PK (Bz-Pro-Phe-Arg-pNA), and Chromozym TH (Tos-Gly-Pro-Arg-pNA) were
purchased from Boehringer, whereas Bz-Phe-Val-Arg-pNA,
Boc-Leu-Gly-Arg-pNA, Bz-Ile-Glu-Gly-Arg-pNA, Z-Lys-Phe-Arg-pNA, and
Sar-Pro-Arg-pNA were obtained from Calbiochem. Acid-soluble collagens
type I from calf skin, rat tail, human placenta, and kangaroo tail were
purchased from Sigma, whereas guinea pig collagen type I was a gift
from Dr. Hideaki Nagase (University of Kansas, Kansas City, KS). In all
cases, collagen integrity was checked by its resistance to degradation
by porcine trypsin.
Methods
Cultivation of Bacteria--
The strain of P. gingivalis (HG66) was a gift of Dr. Roland Arnold (University of
North Carolina, Chapel Hill). The cells were grown in 200 ml of broth
containing 6.0 g of Trypticase Soy broth (Difco), 2.0 g of
yeast extract, 1 mg of hemin, 200 mg of cysteine, 20 mg of
dithiothreitol, and 0.5 mg of menadione (all from Sigma) anaerobically,
at 37 °C for 48 h in an atmosphere of 85% N2, 10%
CO2, 5% H2. The culture was used to inoculate
5 liters of the same broth, which was then incubated anaerobically, at
37 °C for about 48-60 h until the late stationary phase of bacteria
growth (final absorbance at 660 nm > 2).
Proteinase Purification--
The initial steps of gingipain R2
(RGP-2) purification were performed according to the methods designed
for HRGP and KGP isolation (12). Briefly, the cell-free culture fluid
was precipitated with acetone, and the protein pellet was redissolved
in 20 mM Bis-Tris, 150 mM NaCl, 0.02%
NaN3, pH 6.8, containing 1.5 mM
4,4'-dithiopyridine disulfide. The solution was then dialyzed, first
against the above buffer (one change), followed by two changes with
Bis-Tris/NaCl buffer supplemented with 5 mM
CaCl2 but without 4,4'-dithiopyridine disulfide. The
dialyzed fraction was clarified by centrifugation (40,000 × g, 2 h), concentrated by ultrafiltration (Amicon PM-10 membrane), and applied to a Sephadex G-150 column equilibrated with
Bis-Tris/NaCl buffer. The column was developed at a flow rate of 30 ml/h with three peaks of activity on BAPNA being found. The highest
molecular mass activity peak was used for the purification of HRGP,
exactly as described by Pike et al. (12), whereas the low
molecular mass peak (50 kDa), having the majority of the activity on
BAPNA, was pooled, concentrated, extensively dialyzed against 50 mM Bis-Tris, 1 mM CaCl2, pH 6.5, and loaded onto a DE-52 cellulose (Whatman) column (1.5 × 20 cm),
equilibrated with Bis-Tris/CaCl2 buffer at a flow rate of
20 ml/h. The column was washed until the A280 nm
base line fell to zero, followed by application of a gradient of 0-200
mM NaCl in a total volume of 200 ml. Fractions (5 ml) were
assayed for activity on BAPNA. Some activity was found in the void
volume of the column, but the major peak was eluted at about 100 mM NaCl. The latter activity was pooled, dialyzed, and
applied to an arginine-Sepharose column (1.5 × 30 cm, 50 ml) equilibrated with 50 mM Tris, 1 mM
CaCl2, pH 7.4, with 0.02% NaN3 at a flow rate
of 20 ml/h. The column was washed with buffer until activity on BAPNA
fell below 20 mOD/min/µl, and the remaining enzyme then eluted with
0.5 M NaCl. Five pools of activity obtained in this step
(Fig. 1), nonadsorbed (A), retarded (B-D), and
eluted with NaCl (E) were collected, concentrated, and
dialyzed against 25 mM Bis-Tris, pH 6.3. Different isoforms
of gingipain R2 were obtained from these pools by chromatofocusing on a
mono-P column (Pharmacia, fast protein liquid chromatography system)
equilibrated with 25 mM Bis-Tris, pH 6.3, using a pH
gradient developed with 50 ml of 10× diluted Polybuffer 74 (Pharmacia)
adjusted to a pH of 4.0.
Enzyme Activity Assays--
Routinely, amidolytic activities of
gingipains R were measured with L-BAPNA (1 mM)
in 1.0 ml of 0.2 M Tris-HCl, 0.1 M NaCl, 5 mM CaCl2, 10 mM
L-cysteine, pH 7.6, at 37 °C. After a specific time of
incubation, the reaction was stopped by addition of 0.05 ml of glacial
acetic acid, and the O.D. at 405 nm then measured against a blank
sample containing no proteinase. To determine the effect of
glycyl-glycine on RGP activity, buffer (0.1 M Tris-HCl, 5 mM CaCl2, 10 mM cysteine, pH 7.6)
was supplemented to a desired dipeptide concentration by mixing with
1.0 M glycyl-glycine, 5 mM CaCl2,
10 mM cysteine, pH 7.6. To compensate for any change of the
ionic strength to the control without glycyl-glycine, appropriate volumes of 0.1 M Tris, 0.2 M NaCl, 5 mM CaCl2, 10 mM cysteine, pH 7.6, were added. General proteolytic activity was measured with 1.0% (w/v)
azocasein (15), whereas the amount of active enzyme in each batch of
gingipain was determined by active site titration using FFRck (16).
Electrophoresis--
Gingipain purification and protein
degradation was monitored by Tricine SDS-PAGE using the
Tris-HCl/Tricine buffer system (17). To avoid protein degradation
during boiling, all samples were treated with 0.05 mM
FFRck, boiled in nonreducing SDS-treatment buffer, and then reboiled
under reducing conditions. For amino-terminal sequence analysis,
proteins resolved in SDS-PAGE were electrotransferred onto
polyvinylidene difluoride (18). Zymography analysis was performed on
samples solubilized in SDS buffer (4% SDS, 20% glycerol, 0.125 M Tris-HCl, pH 6.8) for 30 min at 37 °C and
electrophoresed on 10% SDS-PAGE with gelatin (0.1 mg/ml, Difco
Laboratories, Detroit, MI) incorporated into the gel (19).
Inactivation of 1-Antichymotrypsin and
1-Proteinase Inhibitor--
The two serpins were
incubated with gingipains at molar ratios from 10:1 to 1000:1 in 0.02 M Tris-HCl, 0.15 M NaCl, 5 mM
CaCl2, 10 mM cysteine, pH 7.6, at 37 °C. At
specific time intervals, aliquots were removed and treated with FFRck
to stop the reaction, with residual inhibitory activity being measured
against the target proteinases, human cathepsin G
( 1-Achy) and neutrophil elastase ( 1-PI).
Inhibitor-treated samples were also analyzed by SDS-PAGE (17).
Kinetics Studies--
The kcat and
Km values were measured at 21 °C using substrates
at concentrations ranging from 0.005 to 2 mM, with a final
concentration of active site titrated enzyme of 3.2 nM in
0.1 M Tris-HCl, 5 mM CaCl2, 10 mM cysteine, 200 mM glycyl-glycine, pH 7.6. In
the absence of glycyl-glycine, 12.5 nM gingipain was used
in 0.2 M Tris-HCl, 5 mM CaCl2, 10 mM cysteine, 0.1 M NaCl, pH 7.6. The assay was
performed in a total volume of 0.2 ml on microplates coated with
albumin (20). To 0.05 ml of substrate, 0.15 ml of enzyme solution was
added with a multichannel pipette, and the initial turnover rate at 12 different substrate concentrations was recorded at 405 nm using a micro
plate reader (Molecular Devices, Vmax). The
Km and kcat values were
calculated using Hyperbolic Regression Analysis, a program
written by J. S. Easterby (University of Liverpool, UK) and
obtained through shareware. Stimulation of gingipain amidolytic
activity on different substrates by glycyl-glycine (stimulation factor)
was determined at substrate concentrations at least five times higher
than the Km value.
Protein Derivatization, Chemical and Enzymatic Fragmentation, and
Peptide Purification--
RGP-2 was denatured in 6 M-guanidine HCl, reduced with dithiothreitol, and
S-carboxymethylated or S-pyridylethylated using protocols provided by Applied Biosystems. After rapid desalting on a
PD-10 column (Pharmacia) equilibrated with 50 mM ammonium bicarbonate, pH 7.8, the modified protein solution was lyophilized. The
derivatized protein was subjected to digestion with cyanogen bromide
(in 70% w/v formic acid) at room temperature in the dark for 18 h
at a 1:1000 molar ratio with respect to methionine. Enzymatic fragmentation was performed with
L-1-tosylamido-2-phenylethyl chloromethyl ketone-treated
trypsin and Glu-C endopeptidase. Generated peptides were separated by
reverse phase high pressure liquid chromatography using a Vydac protein
C18-10 column (4 × 30 mm). The peptides were eluted with 0.1%
trifluoroacetic acid and acetonitrile containing 0.08% trifluoroacetic
acid using a gradient from 0 to 80% acetonitrile over 60 min. Peptides
were monitored at 220 nm and collected manually.
For active site cysteine residue determination, RGP-2 was first labeled
with biotin- -aminocaproyl-Phe-Pro-Arg-chloromethylketone (Hematologie Technologies, Inc., Essex Junction, VT) and then S-pyridylethylated and subjected to proteolytic
fragmentation with trypsin. Biotinylated peptide was purified on
avidin-agarose (Sigma) and analyzed for both amino acid composition and
sequence as described previously (13).
Sequence and Amino Acid Analysis--
Sequence analysis was
performed with an Applied Biosystems 477A pulsed liquid phase sequencer
with on-line phenylthiohydantoin analysis using an Applied Biosystems
120A high pressure liquid chromatography system operated according to
the manufacturer's recommendations. For amino acid analyses, purified
RGP-2 isoforms and peptides were hydrolyzed for 24 h at 110 °C
in 6 N HCl containing 0.1% phenol. The tubes were
evacuated and flashed with nitrogen several times before hydrolysates
were applied to a Beckman System 6300 high performance amino acid
analyzer with a Hewlett Packard 3390A integrator.
Molecular Mass Determination--
The molecular masses of the
purified isoforms of RGP-2 were estimated by SDS-PAGE using the
Tris-HCl/Tricine buffer system (17) and the method of Laemmli (21) on
10 or 12.5% separating gels. Accurate molecular mass measurements were
performed on all major isoforms of RGP-2 employing matrix-assisted
laser desorption ionization, with mass spectra acquired using a Vestec
matrix-assisted laser desorption ionization linear time-of-flight mass
spectrometer (Perspective Biosystems).
 |
RESULTS |
Enzyme Purification--
Gel filtration chromatography of the
acetone precipitate obtained from culture fluids yielded a protein and
activity profile (against BAPNA and Bz-L-Lys-pNA) identical
to that reported previously (12). This time, however, the low molecular
mass active fraction containing the majority of the activity against
BAPNA was used for further purification. Anion-exchange chromatography
of this fraction resulted in the separation of two peaks of activity, one that did not bind to DE-52 cellulose (Vo)
and a second major activity that eluted at 100 mM NaCl
concentration and contained 95% of the total activity. The activity
present in the Vo fraction was not due to the
column overloading because, during its rechromatography, all activity
still passed unretarded through the column. The chromatographic behavior of this fraction resembles that of the 50-kDa gingipain R1
(RGP-1) purified by Chen et al. (11).
The major peak of activity was subjected to affinity chromatography on
an arginine-Sepharose column, with three active fractions being
obtained (Fig. 1): nonbound
(A), retarded (B-D), and bound (E).
Again, the chromatographic behavior of each fraction was checked by
rechromatography, and it was shown that regardless of whether
proteinases were activated with reducing agent or blocked at the
reactive site with tosyl-L-lysine chloromethyl ketone, each
fraction was eluted from the column in a specific manner, apparently
because of differing affinities for arginine residues. All gingipains
in the collected fractions had the same molecular mass except pool A,
which, besides containing the 48.3-kDa band of the native proteinase,
also had a protein band of about 43 kDa (Fig. 1, inset). The
N-terminal amino acid sequence was the same for both proteins,
suggesting that the 43-kDa band represented a C-terminally truncated
enzyme. Curiously, and despite similar or identical apparent molecular
masses, all gingipain fractions differed in specific activity (Table
I), the most active being in fractions B
and C.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 1.
Chromatography of gingipains on
arginine-Sepharose. Fractions from DE-52 ion-exchange
chromatography (see "Experimental Procedures") were applied to an
80-ml arginine-Sepharose column equilibrated with 50 mM
Tris, 1 mM CaCl2, 0.02% NaN3, pH
7.4, and the column was washed extensively with buffer before remaining
proteins were eluted with 0.5 M NaCl. Fractions were
assayed for protein content (A280) and
amidolytic activity against BAPNA. Activity peaks were pooled as
indicated by double-headed arrows, concentrated, and
analyzed by SDS-PAGE (inset). Lane 1, molecular
mass standards; lane 2, acetone precipitate of P. gingivalis HG66 culture media; lane 3, 50-kDa peak of
gingipain R activity from Sephadex G-150; lane 4, RGP-2
after DE-52; lane 5, fraction A; lane 6, fraction
B; lane 7, fraction C; lane 8, fraction D; and
lane 9, fraction E.
|
|
Chromatofocusing Separation of Gingipain Isoforms--
Each
gingipain subfraction was subjected to chromatofocusing, with four
enzyme isoforms being purified (I, II, III, IV) (Fig. 2). Pool A contained an enriched source
of isoform I, as well as an inactive protein component. In pool B,
isoform II was predominant, and in pool C, isoforms II and III
prevailed (Fig. 2). In pool D, the proportion of gingipain isoforms was
shifted toward isoform III, whereas in pool E, isoform IV predominated,
with an additional form eluting from the column at a pH lower than any
other form (data not shown).

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 2.
Chromatofocusing of RGP-2 on mono-P. The
concentrated fraction C of RGP-2 from the arginine-Sepharose column,
with buffer changed to 20 mM Bis-Tris, pH 6.3, by
ultrafiltration, was loaded on a mono-P column equilibrated with the
same buffer. The pH gradient was developed with 50 ml of Polybuffer 74 with pH adjusted to 4. Activity peaks eluted at the same pH after
chromatofocusing of RGP-2 fractions A, B, and C were considered to be
the same isoform of the enzyme, pooled together, concentrated by
ultrafiltration with buffer exchange to 20 mM Bis-Tris, 1 mM CaCl2, 0.02% NaN3, pH 6.5, and
analyzed by SDS-PAGE (inset, a),
isoelectrophoresis (inset, b), and zymography
(inset, c). Lane 1, RGP-2 mixture of
isoforms after DE-52 except inset B, where pI standards were
separated on line 1; lane 2, RGP-2 isoform I; lane
3, isoform II; lane 4, isoform III; and lane
5, isoform IV.
|
|
Molecular Mass, pI, and Zymography Analysis--
All isoforms had
identical N-terminal sequences as well as the same electrophoretic
mobility in SDS-PAGE (Fig. 2, inset A), equivalent to a
molecular mass of 48.3 ± 0.4 kDa as determined using laser
densitometry scanning of several gels. The masses of 48,019 Da (isoform
I-B), 48,031 Da (isoform II-B), 48,138 kDa (isoform I-C), 48,078 Da
(isoform II-C), 48,256 Da (isoform III-C), and 48,369 Da (isoform C-IV)
were determined by matrix-assisted laser desorption
ionization-time-of-flight, and these results are in keeping with those
from SDS-PAGE. In addition to differences in molecular mass, the
various isoforms also differed in isoelectric points that were
determined to be 5.21, 5.09, 5.03, and 4.96 for isoforms from I to IV,
respectively (Fig. 2, inset B). In contrast, the pI of HRGP
was found to be 3.74 (data not shown). The difference in pI of RGP-2
isoforms correlated with their mobility in gelatin zymography gels
(Fig. 2, inset C) in that forms with the higher pI
were more retarded in the gel. From comparison of band patterns in
crude and partially purified RGP-2 preparations, it is apparent that
isoform II (pI 5.09) is the major form of this gingipain released by
P. gingivalis HG66.
Structure of RGP-2--
The gene encoding RGP-2 has been cloned
and sequenced from two different strains of P. gingivalis
(GenBank accession nos. D64081 and U85038). It encodes a polypeptide
chain with a 227-amino acid prepropeptide followed by a catalytic
domain of 507 residues. The calculated molecular mass of 55 kDa for the catalytic domain was 7 kDa larger than its mass determined by mass
spectroscopy and SDS-PAGE, indicating a truncation at the C terminus.
The differences in the molecular mass among different RGP-2 isoforms
were small (48,148 ± 135 Da), implying that the polypeptide chain
of mature RGP-2 was truncated around residue 433 (calculated mass 48, 118 Da) (Fig. 3). The amino acid analysis of the isoforms failed to show any significant differences among them
and consistently indicated that the various polypeptide chains were a
few amino acid residues shorter than anticipated from molecular mass
analysis (data not shown). To clarify this discrepancy, the primary
structure of RGP-2 was determined by sequence analysis of CNBr and
proteolytic enzyme (trypsin and V8 protease)-generated fragments of
C-pyridylethylated protein. Except for a seven-amino acid residue
peptide (396DGKAIIK), all other fragments of RGP-2 could be
purified and sequenced, indicating that RGP-2 is composed of 422 amino
acid residues with the C-terminal sequence -Gly-Tyr-Asn-Lys-COOH
apparently being formed through truncation of the gingipain polypeptide
chain by a Lys-specific proteinase (Fig. 3B). Amino acid
analysis confirms such a structure (Fig. 3A), although its
calculated molecular mass is about 1,000 Da lower than determined from
the mass spectroscopy analysis. This discrepancy is most likely because
of some amino acid side chain modifications that additionally lead to
formation of the RGP-2 isoforms. Apparently, these variations had no
effect on enzyme properties, as in screening experiments it was found that the isoforms were indistinguishable with regard to stability, pH
optima, kinetic characteristic, and proteolytic activity. Therefore, in
experiments described below comparing properties of RGP-2 and HRGP,
either fraction B from the arginine-Sepharose chromatography step or
purified isoform II was used.

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 3.
Amino acid composition of RGP-2
(A) and comparison of the primary structure of RGP-2 and
HRGP catalytic domain (B). The amino acid composition
of RGP-2 was compared with the composition calculated from the RGP-2
primary structure determined at the protein level (sequence in
capital letters in panel B) or inferred from the
nucleotide sequence encoding the entire catalytic domain
(numbers in brackets). In panel B, the
identical amino acids in the HRGP catalytic domain are marked by
bullets. A single gap ( ) in HRGP sequence was introduced
to improve alignment. An underlined fragment of RGP-2 has not been
sequenced, and it is assumed that it is covalently modified either on a
Lys or Asp residue. The fragment of 55 residues (434-489) in the
C-terminal region of the initial polypeptide chain of RGP-2 and
40-residue (433-473) fragment of HRGP catalytic domain share no
similarity. These fragments were excluded from alignment and are marked
with dots.
|
|
It has been suggested that rgp-1 and rgp-2/rgpB
genes were created by domain-specific rearrangement between the two
Arg-gingipain-encoding genes in P. gingivalis, possible
through nonreciprocal recombination (22). Indeed, the primary structure
of RGP-2 is generally identical to the catalytic domain of HRGP,
although both polypeptides differ considerably within the C-terminal
region (Fig. 3). This identity also applies to the region containing
the active site cysteine residue, whose exact location in HRGP has been
a matter of controversy (13, 23). This prompted us to determine the
position of this residue in RGP-2 by specific biotinylation of the
active site residue using
biotin- -aminocaproyl-Phe-Pro-Arg-chloromethylketone (24). The
labeling was found at Cys-244 (data not shown), in agreement with the
observation of Nishikata and Yoshimura (23).
Stability--
Both of the RGP-2 isoforms as well as HRGP showed
very similar pH stability profiles. In the absence of cysteine, all
were found to be stable over a pH range of 4.5-8.5 over several hours; however, in its presence the enzymes only remained stable for similar
time periods at pH values between 7.5 and 8.5, losing activity rapidly
outside this pH range. In contrast to Ca2+, which
stabilized enzyme activity, glycyl-glycine considerably enhanced the
inactivation rate. Gingipains in neutral pH in buffers containing
Ca2+ (1-5 mM CaCl2) were stable
for months in ice and indefinitely if stored frozen at 20 °C.
Kinetic Characteristics--
The optimum pH for the hydrolysis of
p-nitroanilide substrates was 8.0 for both RGP-2 and HRGP.
In contrast, with protein substrates, such as azocasein, the maximum
proteolytic activity for HRGP was at pH 7.5, whereas RGP-2 showed a
very broad and flat spectrum of proteolytic activity in the pH
range from pH 5.0 (50% activity) to a maximum at pH 9.5 (100%). At a
higher pH, proteolytic activity decreased sharply, apparently because of enzyme instability.
Without reducing agents, the activities of purified RGP-2 and HRGP were
below 1% of their activity in the presence of 10 mM cysteine, the most effective reducing agent for activation of gingipains. Although low levels of cysteine were able to activate both
proteinases, 1 and 5 mM were required for the development of full proteolytic activity for RGP-2 and HRGP, respectively. A
similar effect was exerted by glutathione and cysteamine, with maximum
activity at concentrations higher than 5 mM. In contrast, dithiothreitol and 2-mercaptoethanol were less effective gingipain activators, requiring a high concentration (100 mM) for
full HRGP activation (60-80% of enzyme activity in presence of 10 mM cysteine). Maximum RGP-2 proteolytic activity (80-90%
of cysteine-activated proteinase) was obtained with a 1-5
mM concentration of these reducing agents, with the enzyme
being denatured at higher values.
The gingipains amidolytic activity against BAPNA was also strongly
dependent on cysteine and cysteamine concentration, with the effect
being most profound for activation of HRGP (Fig.
4, A and B). The
increase of amidolytic activity of gingipains could also be achieved in
the presence of glycyl-glycine, and at constant reducing agent levels
it was clearly dependent on the dipeptide concentration. However,
gingipains general proteolytic activity was not affected by
glycyl-glycine (Fig. 4C).

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 4.
Effect of reducing agent and glycyl-glycine
on gingipains R activity. Amidolytic activity of HRGP
(A) and RGP-2 (B) was determined in the presence
of 10, 50, and 200 mM of a reducing agent without
glycyl-glycine (filled bars) or with 200 mM
glycyl-glycine added to the assay buffer (light shadowed
bars). Proteolytic ( , ) and amidolytic activity ( , )
of HRGP ( , ) and RGP-2 ( , ) was determined in the presence
of 10 mM cysteine and increased concentration of the
dipeptide (C). Enzyme activity in the presence of 10 mM cysteine was taken as 100%.
|
|
To further investigate gingipains specificity and the effect of
glycyl-glycine on their activities, the Km and
kcat values for several commercially available
arginine-containing substrates were determined in the presence and
absence of this dipeptide (Fig. 5). In
the absence of glycyl-glycine, the Km was in the
range of 9.5-56.3 µM and 13.9-128 µM for
HRGP and RGP-2, respectively. In comparison, the Km
values for substrates with a P2 glycine residue (I and
IX-XVI) were generally higher for RGP-2. No such correlation was
apparent for HRGP. Altogether, the kcat values
were slightly higher for RGP-2 than for HRGP. In the presence of
glycyl-glycine, both the Km and
kcat increased in parallel for the same
substrate, without much effect on the
kcat/Km ratio, which is a
measure of enzyme catalytic efficiency. Comparison of the
kcat/Km ratio revealed that
both RGPs have similar general catalytic potency on the substrates tested, with Z-Arg-Arg-pNA and Leu-Thr-Arg-pNA being, respectively, the
least and the most sensitive substrates for gingipains. In general,
beside Z-Arg-Arg-pNA, substrates with P2 proline residue (compounds XIX-XXI) were relatively poor substrates for both
gingipains, with the exception of Tos-Gly-Pro-Arg-pNA (XXII).

View larger version (56K):
[in this window]
[in a new window]
|
Fig. 5.
Histogram of substrate specificity of HRGP
(A) and RGP-2 (B) toward synthetic peptidyl
p-nitroanilides with general formula of -Xaa-Arg-pNA.
The kcat and Km values were
measured in the absence (filled bars) and the presence
(empty bars) of 200 mM glycyl-glycine in buffer
containing 10 mM cysteine. The stimulation factor
(shaded bars) shows how enzyme activity against a given
substrate is increased in the presence of 200 mM
glycyl-glycine.
|
|
At substrate concentrations significantly higher than the
Km, the increase in gingipains activation by
glycyl-glycine (stimulation factor) was very closely correlated to the
change of the kcat value (data not shown). In
general, the substrate turnover stimulation by glycyl-glycine was about
2-fold higher for HRGP than RGP-2, and for both gingipains it was
dependent on peptide structure. For substrates with P2
hydrophobic residues (Fig. 5, compounds II, V, VI, XVII, and XVIII),
the stimulation factor was the lowest. Also, stimulation was relatively
low for substrates with hydrophobic or positively charged residues at P3. In contrast, a P3 Glu (compounds XIV, XV,
and XX) seemed to correlate with glycyl-glycine stimulation of
gingipains amidolytic activity.
Comparison of Gingipain Proteolytic Activity--
Using
equimolar amounts of HRGP and RGP-2, it was found that the general
proteolytic activity, using azocasein or azocoll, of HRGP was five
times higher than that of RGP-2, despite the fact that both enzymes
were equally active on synthetic substrates (data not shown). Although
proteolytic degradation of azocasein and azocoll was not affected by
glycyl-glycine, the dipeptide enhanced proteolytic inactivation of
1-Achy (Fig. 6). The
acceleration was not a result of a glycyl-glycine effect on serpin
structure as antichymotrypsin inactivation by Staphylococcus
aureus metalloproteinase, trypsin, and KGP was unchanged in the
presence of the dipeptide (data not shown). In comparison with general
proteolytic activity, antichymotrypsin inactivation occurs through a
single peptide bond cleavage at the P7' residue
(-Val-Glu-Thr-Arg * Ile-) within the reactive site loop. The sequence
of the cleavage site resembles the structure of substrates whose
turnover is enhanced by glycyl-glycine to the highest degree. On the
other hand, neither HRGP nor RGP-2 was able to inactivate
1-PI, in keeping with the fact that there is no arginine
residue within the reactive site loop of this inhibitor. These data,
however, contradict a report that a cysteine proteinase from P. gingivalis, apparently identical with one of the RGP forms described in this report, degrades 1-PI (25).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 6.
Inactivation of
1-Achy by gingipains R. 1-Achy at a final concentration of 6.7 µM
was incubated with of 33.5 nM HRGP ( , ) or 33.5 nM RGP-2 ( , ) in 50 mM HEPES, 2 mM cysteine, pH 7.6, with 200 mM glycyl-glycine
(filled symbols) or without the dipeptide (open
symbols) at 37 °C. At specific time intervals, 34-µl aliquots
were transferred to 0.956 µl of 50 mM Hepes, 0.5 M NaCl, pH 7.6, containing 20 µM leupeptin;
after 5 min, 1-Achy residual inhibitory activity against
cathepsin G was determined.
|
|
P. gingivalis elaborates collagenolytic activity, and this
activity has, at least partially, been suggested to be due to
gingipain-like arginine-specific cysteine proteinases (25, 26). To
compare the collagenolytic activity of gingipains described in this
report, type I collagen from human placenta was incubated with KGP,
HRGP, and RGP-2 for 24 h at 25 and at 37 °C. Although P. gingivalis W50 vesicles and culture medium of strain HG66
possessed significant collagenolytic activity (Fig.
7, lanes 2 and 3),
no collagen degradation by purified gingipains was observed by SDS-PAGE
if the reaction was stopped by addition of FFRck and if the sample was
first boiled in nonreducing sample buffer (Fig. 7; lanes 4-6, 10, 13, and 18). However, if pretreatment with inhibitor was omitted (Fig. 7;
lanes 12, 15, 16, and 19) or inhibitor treated sample was directly
boiled in reducing conditions (Fig. 7; lanes 11,
14, and 17) extensive degradation of this
substrate was observed even without any preincubation of collagen with
gingipains. Exactly the same results were obtained using type I
collagen from calf and guinea pig skin or rat and kangaroo tail (data
not shown). The ineffectiveness of the inhibitor treatment without
pre-boiling in nonreducing conditions is apparently due to the fact
that the high concentration of dithiothreitol in sample buffer
activates the remaining enzyme, which in latent state is not inhibited
by FFRck. Therefore, it is obvious that collagen degradation occurred
during the initial period of sample heating, apparently because of its
instant unfolding in the presence of SDS, whereas gingipain R remained
active for a longer time. In addition, 1-PI degradation
could only be observed in SDS-PAGE if the sample was not pretreated
with FFRck prior to boiling in reducing conditions (data not shown),
and this may explain the conflicting results described above (25).

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 7.
Degradation of type I collagen by
gingipains. Human placental type I collagen (25 µg) was
incubated with P. gingivalis W50 vesicles (lane
2) or acetone precipitate of culture medium from strain HG66
(lane 3), or with purified gingipains, 2 µg of KGP
(lanes 4, 10-12), 2 µg of HRGP (lanes
5, 17-19), and 5 µg of RGP-2 (lanes 6,
13-15) or 0.2 µg of RGP-2 (line 16) in 50 mM Tris, 0.15 M NaCl, 10 mM
cysteine, pH 7.6, at 30 °C for 24 h. In samples loaded in
lanes 2-6, 10, 13, and 18,
the reaction was stopped by addition of FFRck at 50 µM.
The samples were first boiled in sample buffer without reducing agent
and then reboiled with 5% dithiothreitol before being applied on the
gel. Samples in lanes 12, 15, 16, and
19 were heated at 100 °C with 5% dithiothreitol in
SDS-PAGE sample buffer without inhibitor pretreatment, whereas samples
in lanes 11, 14, and 17, although
being treated with FFRck, were directly boiled under reducing
conditions. Molecular mass standards are in lanes 1 and
8, and collagen controls (25 and 5 µg, respectively) are
in lanes 7 and 9. To check the integrity of
collagen, one sample was incubated with 5 µg of porcine pancreatic
trypsin and directly boiled in reducing sample buffer (lane
20).
|
|
Without proper precaution, gingipains undergo fragmentation during
boiling in SDS-reducing agent treatment buffer, with KGP being least
susceptible to autodegradation (Fig.
8A). Interestingly, the
catalytic domain of HRGP is apparently more susceptible to degradation
than any other component of this proteinase-hemagglutinin/adhesin complex, as determined by laser densitometry scanning of the gel (data
not shown).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 8.
Autodigestion of gingipains and unusual
electrophoretic behavior of HRGP. A, Tricine SDS-PAGE
system. Samples of RGP-2 (lanes 2 and 3), HRGP
(lanes 4 and 5), and KGP (lanes 6 and
7) were prepared either by enzyme treatment with 50 µM FFRck, boiling in nonreducing sample buffer and then
reboiling in 5% dithiothreitol before loading on gel (lanes
2, 4, and 6), or by direct heating in
reducing conditions (lanes 3, 5, and
7). B-D, Laemmli 12% gel system. Samples of
enzymes were prepared by inhibitor treatment and initial boiling in
nonreducing conditions. Lane 9, RGP-2; lane 10,
HRGP; lane 11, KGP. C and D,
gingipains were Western blotted using chicken antibodies against the
N-terminal fragment of gingipains catalytic domains (C) or
against the 40-kDa hemagglutinin/adhesin domain of KGP. Before being
blocked with albumin, membranes were transiently stained with Ponceau
S, and protein bands were equivalent to the gingipains catalytic domain
or 44-kDa hemagglutinin/adhesin domain marked.
|
|
Polypeptide components of the HRGP complex show unusual electrophoretic
behavior in different SDS-PAGE systems (Fig. 8B). In gel
systems with Tricine as tracing ion, the HRGP complex resolves into
four major polypeptides of 49.5 kDa (catalytic domain), 43 kDa, 23.3 kDa, and 15.9 kDa. In the Laemmli system, however, the catalytic domain
comigrates with a 43-kDa adhesin domain, as was confirmed by Western
blotting using specific antibodies (Fig. 8, C and
D). In addition, the lower molecular mass band of HRGP divided into two bands of molecular mass of 17 and 16 kDa. In contrast,
the KGP band pattern was unchanged in different electrophoresis systems.
 |
DISCUSSION |
Several genes for arginine-specific proteases of P. gingivalis have been identified, including agp
(P. gingivalis 381) (27), rgp-1 (HG66) (13),
prtR (W50) (28), prpR1 (W50) (29), and prtH (W58) (30). Despite some significant differences in
nucleotide sequence, size, and physical organization, all of these
genes are believed to represent a single genetic locus that is either strain variable or has suffered recombination between repeat regions during or prior to cloning (31, 32). In addition, the second locus
encoding a similar proteinase (rgpB and rgp-2
from ATCC 33277 and HG66, respectively) has been cloned and sequenced
(22, 33), and it is now apparent that the arginine-specific activity of
P. gingivalis is derived from the products of just two genes (14). Several different forms of such enzymes have already been purified, but due to the lack of structural data, it is impossible to
predict from which gene they were derived (for review see Ref. 8). One
of the exceptions is the proteinases, referred to as gingipains R,
purified from P. gingivalis HG66 (11, 12) and their
counterparts isolated from W50 (34-36). It is now unambiguous that
both the 50-kDa RGP-1 and high molecular mass forms of the enzyme
(HRGP) are derived from the initial translation product of the
rgp-1 gene (13). In contrast, the enzyme described in this
report (RGP-2) is evidently encoded by a second gene,
rgp-2.
For a considerable length of time, our group confused the 50-kDa RGP-1
with RGP-2. After the report on RGP-1 purification and characterization
had been published (11), we modified the original procedure to improve
enzyme yield; however, by this new procedure we obtained RGP-2, a fact
we were not aware of until both rgp-1 and rgp-2
genes were cloned and sequenced. This means that RGP-2, not the 50-kDa
RGP-1 originally isolated (11), was used in all work published since
1993.
In contrast to other strains of P. gingivalis where
gingipain activity is predominantly membrane associated (10), RGP-2, together with HRGP and KGP, constitutes the majority of soluble protein
secreted into the culture media by strain HG66 (Fig. 1, inset). Thus, this makes the strain an excellent source of
easily purified soluble proteinases and, as shown after the first step of purification (gel filtration on Sephadex G-150), large amounts (Table I) of nearly homogenous RGP-2 can be obtained. However, when
purified in this way, RGP-2 shows considerable heterogeneity in its
affinity for arginine-Sepharose, apparently due to the occurrence of
discrete isoforms. The RGP-2 isoforms have the same primary structure,
and comparison to the amino acid sequence inferred from the nucleotide
sequence of the rgp-2 gene revealed that the mature protein
is truncated at its C terminus. Apparently, the polypeptide chain of
RGP-2 is proteolytically processed at Lys422, indicating
involvement of a lysine-specific proteinase in this process. Presently,
it is unknown in which cell compartment this processing takes place or
if there is any pathophysiological meaning, but it is tempting to
speculate that it may occur on bacterial cell surfaces leading to
proteinase(s) release into culture medium. Protein shedding from
bacterial surfaces by endogenous microbial proteinases has been
recently recognized. For example, the Streptococcus pyogenes
cysteine proteinase (streptopain) releases several biologically active
polypeptides from bacterial cell surfaces, including C5a peptidase,
which likely contributes to the pathogenicity and virulence of this
bacterium (37).
The polypeptide structures of the RGP-2 isoforms are evidently nearly
identical. Therefore, any differences in pI, molecular mass, affinity
to arginine, and electrophoretic mobility in zymography gel are likely
to be due to variations within a 650-1000-Da moiety attached to the
polypeptide chain. The nature of this modification is presently
unknown, but we hypothesize that it may be due to attachment to a part
of a lipopolysaccharide moiety because a post-translationally
lipid-modified form of RGP, which migrates to the 70-80-kDa region on
SDS-PAGE, has been detected with monoclonal antibodies to
lipopolysaccharide (35). This assumption is further supported by the
fact that in strains W50, W83, OMGS 100 and ATCC 33277, the 70-80 kDa
form of enzyme is exclusively membrane associated, while being absent
in membranous fraction of HG66, indicating its likely release in
modified forms into the media (10) in this latter strain. The
lipopolysaccharide-modified enzymes have been purified from culture
media of P. gingivalis W50 (36) and, with regard to primary
structure and gene origin, they seem to correspond to both RGP-2 and
the catalytic domains of HRGP from HG66.
The numerous attempts to purify arginine-specific proteinases from
different strains and cellular fractions of P. gingivalis in
most cases have led to the separation of 43-55-kDa proteins (for
review see Ref. 8). Only in the case of a 53-kDa enzyme from W50,
referred to as PrpRI, was it shown that it is a noncovalent dimer of a
catalytic domain ( -chain) and the same size -chain (35). The
corresponding enzyme purified from HG66, 95-kDa RGP-1 (HRGP), occurs as
a mixture of three isoforms in which the 50-kDa catalytic domain is
associated with either HGP44, a counterpart of the -chain of PrpRI,
or with fragments (HGP15, HGP17, and HGP27) derived from the C-terminal
portion of the initial polyprotein encoded by rgp-1 (8, 13).
Regardless of the gel system, the catalytic domain of HRGP and RGP-2
have the same electrophoretic mobility, and in Tricine-SDS-PAGE the
catalytic chain of HRGP is separated from the HGP44 ( -chain)
hemagglutinin/adhesin domain (Fig. 8). In the Laemmli system, however,
regardless of the acrylamide concentration, both chains migrate with
exactly the same mobility, equivalent to a molecular mass of 49.5 ± 4.5 kDa. Using Western blotting, as described in Fig. 8, it was also
determined that in other strains (W50, W83, ATCC 33277, 381, and OMGS
100), the catalytic domain of HRGP ( -chain) and
hemagglutinin/adhesin domain HGP44 ( -chain) have the same mobility
in the SDS-PAGE Laemmli system, although they migrate separately in the
Tricine-SDS-PAGE (data not shown). Therefore, it is likely that from
those strains a form of Arg-specific gingipain consisting of the
catalytic domain and HGP44 was purified, but its composite structure
was not perceived due to abnormal electrophoretic behavior. The
observed comigration of the catalytic and hemagglutinin domain resolves
considerable confusion regarding the hemagglutinin activity of purified
arginine-specific cysteine proteinases. Because it was unequivocally
shown that neither RGP-2 nor the HRGP catalytic domain (50-kDa RGP-1)
have hemagglutinin activity (38), this activity associated with
purified proteinases (39) was apparently the result of the
heterodimeric structure of the enzyme. Therefore, the term
hemagglutining protease (23) should be used with caution, at least
until the direct involvement of the proteinase catalytic domain in
erythrocyte recognition is verified experimentally.
In many respects, RGP-2 and HRGP show very similar properties including
stability, activation by various reducing agents, and pH optimum for
the hydrolysis of p-nitroanilide substrates, and this is not
surprising when one considers the high degree of identity of their
catalytic chains. Also, specificity against synthetic substrates with
P1 arginine residue, expressed as the kcat/Km ratio, was similar
for both forms of RGP, and no clear preference was observed for
particular amino acid residues at the P2 and/or P3 position, as
described previously by others (25, 26). This contradiction is
apparently due to the fact that earlier conclusions on enzyme
specificity were suggested after examining the turnover rate of only a
limited number of substrates.
One unique property of RGP is the stimulation of their amidolytic
activity by amino acids and dipeptides, particularly glycyl-glycine (40). This feature was successfully utilized to detect P. gingivalis in subgingival bacterial plaque by a simple assay of
glycyl-glycine stimulated activity against BAPNA in samples of
crevicular fluid collected from discrete periodontitis sites (20). In
the present work, it was also shown that dipeptide stimulation can be
used as a tool to distinguish between RGP-1 and RGP-2 related forms, as
activity of the former enzyme against BAPNA was stimulated 18-fold in
the presence of 200 mM glycyl-glycine in comparison with
RGP-2, whose activity was increased only 7-fold.
The stimulation of RGP activity is due to an increase of the
kcat value, but the enzyme catalytic potency
measured as the ratio kcat/Km
remains unaffected because of a parallel increase in
Km (Fig. 5). Apparently, in the presence of
glycyl-glycine, nonproductive, high affinity binding of the substrate
arginine side chain is eliminated. This explanation is further
supported by the observation that the stimulation factor for given
substrates strongly depends on its peptide composition. In addition,
dipeptides do not have any effect on the general proteolytic activity
of RGPs (Fig. 4C) or on the inactivation rate of cathepsin
G.2 In contrast, however, the
rate of 1-Achy inactivation was enhanced by
glycyl-glycine, indicating that for certain macromolecular substrates
of gingipains, where a single Arg-Xaa peptide bond is cleaved,
dipeptides may have a stimulatory effect as was previously noticed for
C3a degradation by RGP-1 (41). The above observations rejuvenate the
hypothesis suggested earlier (40) that dipeptide stimulation of RGP
activity may represent bacterial adaptation to the natural environment,
which is potentially reached in glycine-containing peptides released
from degraded collagen fibers.
Despite the fact that HRGP and RGP-2 are equally active on synthetic
substrates, HRGP general proteolytic activity is 5-fold higher, and
this is particularly noticeable in 1-Achy inactivation. In addition, both enzymes also differ considerably in pH optimum for
proteolytic activity. Whereas HRGP was most active in slightly alkaline
pH, RGP-2 was functional in a broad pH range with a maximum at pH 9.5. This feature may represent an important adaptation of the P. gingivalis proteolytic system to the environment and explain why
both genes are maintained in all strains so far examined (36).
One of the clinical hallmarks of periodontitis is degradation of a
periodontal ligament, the fibrous attachment of the tooth inserting
into cementum of the root and into the alveolar bone. The main collagen
types within the periodontium ligament, and gingival connective tissue
as well, are types I, III, and V, with the type I being the most
abundant (3). Although degradation of all three types of collagen by
proteinases produced by periodontopathogens may significantly
contribute to the pathology of the disease, only type I collagen
degradation has been extensively studied. For years, P. gingivalis collagenolytic activity was a source of controversy
since some authors attributed the ability to degrade type I collagen to
trypsin-like proteinases, whereas others found no such activity
associated with these enzymes (for review see Ref. 8). More recently,
collagenolytic activity was directly linked to purified proteinases
that undoubtedly represent one form of RGP (25, 26). In this report, we
were unable to show degradation of type I collagen even by large
amounts of purified gingipains, although collagenolytic activity was
found in crude preparations (Fig. 7). However, if a sample of gingipain
with collagen was boiled directly in reduced SDS-PAGE sample buffer, without prior inhibitor treatment, total protein degradation was observed. Apparently, during the denaturation process, the
proteinase-impregnable structure of collagen was lost faster than
gingipain activity, and denatured collagen (gelatin) became a substrate
whose degradation was enhanced by SDS (42), temperature, and a highly
reducing environment. Other examples of artificial protein degradation by RGPs during boiling in the reducing SDS-PAGE sample buffer include
those involving -1-PI, cystatin C, and -2-macroglobulin. The
first inhibitor sustains its antielastase activity even after long
incubation with large amounts of RGP, but if the sample is not treated
with FFRck before SDS-PAGE, the inhibitor is totally degraded,
apparently during sample denaturation (data not shown). Similarly,
cystatin C in its native conformation is only cleaved at a single
peptide bond near the N terminus (Arg6-Leu7) by
RGP but is totally degraded during boiling in SDS (43). Gingipains,
themselves, also undergo extensive autodegradation, as shown during
sample preparation for SDS-PAGE (Fig. 8A).
The list of potential substrates of proteinases elaborated by P. gingivalis is long and includes proteinase inhibitors,
immunoglobulins, iron transporting/sequestering proteins, coagulation,
fibrinolytic, complement, and kallikrein/kinin cascade proteins,
proteins of extracellular matrix, and bactericidal proteins and
peptides (for references see Ref. 8). Certainly, degradation of some of
these proteins occurs in physiological conditions, but others may just be an artifact associated with sample denaturation in a highly reducing
condition of SDS-PAGE sample buffer. Therefore, the data on protein
degradation by P. gingivalis crude fractions and purified trypsin-like proteinase assessed by SDS-PAGE should be treated with
caution.
In summary, from accumulating data it is becoming apparent that the
pathophysiological function of gingipains is not just a random
degradation of host proteins to provide nutrients for this
asaccharolytic bacterium but rather a sophisticated utilization of host
systems toward the benefit of the pathogen. In many cases, this purpose
can be achieved by limited proteolysis at basic residues of factors
involved in blood clotting and fibrinolysis, kinin generation,
complement activation, and proteinase-activated receptors and
signaling. Indeed, gingipains were found to be able to affect each of
these otherwise tightly regulated cascades (41,
44-48).3 In addition,
gingipains R seem to carry on significant housekeeping functions that
are important for bacterial cell physiology and that are also based on
limited hydrolysis at strictly selected Arg residues, including
proteolytic processing of bacterial precursor proteins (profimbrilin)
(49, 50), the 75-kDa major outer membrane protein (50), and
progingipain K (51), in this way being responsible for fimbriae
assembly and hemagglutinin activity expression by P. gingivalis.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grant DE 09761 (to J. T.) and by Grant 6 P204A 019 11 from the State Committee of Scientific Research (KBN, Poland) (to J. P.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed. Tel.: 706-542-1711;
Fax: 706-542-3719; E-mail: potempa{at}arches.uga.edu.
The abbreviations used are:
RGP-1, 50-kDa
gingipain R1 or arginine-specific gingipain 1; HRGP, 95-kDa gingipain
R1 or high molecular mass arginine-specific gingipain 1; KGP, lysine-specific gingipain or gingipain K; BAPNA, benzoyl-L-arginine-p-nitroanilideFFRck, Phe-Phe-Arg-chloromethyl ketonePAGE, polyacrylamide gel
electrophoresis 1-Achy, 1-antichymotrypsin.
2
J. Potempa, unpublished results.
3
A. Lourbakos, C. Chinni, P. Thompson, J. Potempa, J. Travis, E. J. Mackie, and R. N. Pike, manuscript in
preparation.
 |
REFERENCES |
-
Shaw, J. H.
(1987)
N. Engl. J. Med.
317,
996-1004[Medline]
[Order article via Infotrieve]
-
Williams, R. C.
(1990)
N. Engl. J. Med.
422,
373-382
-
Williams, D. M.,
Huges, F. J.,
Odell, E. W.,
and Farthing, P. M.
(1992)
Pathology of Periodontal Disease, Oxford University Press, Oxford
-
Socransky, S. S.,
and Haffajee, A. D.
(1992)
J. Periodontol.
63,
322-331[Medline]
[Order article via Infotrieve]
-
Holt, S. C.,
Ebersole, J.,
Felton, J.,
Brunsvold, M.,
and Kornmann, K. S.
(1987)
Science
239,
55-57
-
Persson, G. R.,
Engel, D.,
Whitney, C.,
et al..
(1994)
Infect. Immun.
62,
1026-1031[Abstract/Free Full Text]
-
Cutler, C. W.,
Kalmar, J. R.,
and Genco, C. A.
(1995)
Trends Microbiol.
3,
35-51
-
Potempa, J.,
Pike, R.,
and Travis, J.
(1995)
Prospect. Drug Discovery Design
2,
445-458[CrossRef]
-
Grenier, D.,
and McBride, B. C.
(1989)
Infect. Immun.
57,
3265-3269[Abstract/Free Full Text]
-
Potempa, J.,
Pike, R.,
and Travis, J.
(1996)
Infect. Immun.
63,
1176-1182[Abstract]
-
Chen, Z. X.,
Potempa, J.,
Polanowski, A.,
Wikström, M.,
and Travis, J.
(1992)
J. Biol. Chem.
267,
18896-18901[Abstract/Free Full Text]
-
Pike, R.,
McGraw, W.,
Potempa, J.,
and Travis, J.
(1994)
J. Biol. Chem.
269,
406-411[Abstract/Free Full Text]
-
Pavloff, N.,
Potempa, J.,
Pike, R. N.,
Prochazka, V.,
Kiefer, M. C.,
Travis, J.,
and Barr, P. J.
(1995)
J. Biol. Chem.
270,
1007-1010[Abstract/Free Full Text]
-
Nakayama, K.,
Kadowaki, T.,
Okamoto, K.,
and Yamamoto, K.
(1995)
J. Biol. Chem.
270,
23619-23626[Abstract/Free Full Text]
-
Barrett, A. J.,
and Kirschke, H.
(1981)
Methods Enzymol.
80,
535-561
-
Potempa, J.,
Pike, R.,
and Travis, J.
(1997)
Biochemistry
378,
223-230
-
Schägger, H.,
and von Jagow, G.
(1987)
Anal. Biochem.
166,
368-379[CrossRef][Medline]
[Order article via Infotrieve]
-
Matsudaira, P.
(1987)
J. Biol. Chem.
262,
10035-10038[Abstract/Free Full Text]
-
Heussen, C.,
and Dowdle, E. B.
(1980)
Anal. Biochem.
102,
196-202[CrossRef][Medline]
[Order article via Infotrieve]
-
Wikström, M.,
Potempa, J.,
Polanowski, A.,
Travis, J.,
and Renvert, S.
(1994)
J. Periodontol.
65,
47-55[Medline]
[Order article via Infotrieve]
-
Laemmli, U. K.
(1970)
Nature
227,
680-685[CrossRef][Medline]
[Order article via Infotrieve]
-
Nakayama, K.
(1997)
Microbiol. Immunol.
41,
185-196[Medline]
[Order article via Infotrieve]
-
Nishikata, M.,
and Yoshimura, F.
(1995)
Biochem. Mol. Biol. Int.
37,
547-553[Medline]
[Order article via Infotrieve]
-
Pavloff, N.,
Pemberton, P. A.,
Potempa, J.,
Chen, W.-C. A.,
Pike, R. N.,
Prochazka, V.,
Kiefer, M. C.,
Travis, J.,
and Barr, P. J.
(1997)
J. Biol. Chem.
272,
1595-1600[Abstract/Free Full Text]
-
Bedi, G. S.,
and Williams, T.
(1994)
J. Biol. Chem.
269,
599-606[Abstract/Free Full Text]
-
Kadowaki, T.,
Yoneda, M.,
Okamoto, K.,
Maeda, K.,
and Yamamoto, K.
(1994)
J. Biol. Chem.
269,
21371-21378[Abstract/Free Full Text]
-
Okamoto, K.,
Misumi, Y.,
Kadowaki, T.,
Yoneda, M.,
Yamamoto, K.,
and Ikehara, Y.
(1995)
Arch. Biochem. Biophys.
316,
917-925[CrossRef][Medline]
[Order article via Infotrieve]
-
Kirszbaum, L.,
Sotiropoulos, C.,
Jackson, C.,
Cleal, S.,
Slakeski, N.,
and Reynolds, E. C.
(1995)
Biochem. Biophys. Res. Commun.
207,
424-431[CrossRef][Medline]
[Order article via Infotrieve]
-
Aduse-Opoku, J.,
Muir, J.,
Slaney, J. M.,
Rangarajan, N.,
and Curtis, M. A.
(1995)
Infect. Immun.
63,
4744-4754[Abstract]
-
Fletcher, H. M.,
Scheinkein, H. A.,
and Macrina, F. L.
(1994)
Infect. Immun.
62,
4297-4286
-
Potempa, J.,
Pavloff, N.,
and Travis, J.
(1995)
Trends Microbiol.
3,
430-434[CrossRef][Medline]
[Order article via Infotrieve]
-
Barkocy-Gallagher, H. N.,
Patti, J. M.,
Whitlock, J.,
Progulske-Fox, A.,
and Lantz, M. S.
(1996)
J. Bacteriol.
178,
2734-2741[Abstract/Free Full Text]
-
Mikolajczyk-Pawlinska, J.,
Kordula, T.,
Pavloff, N.,
Pemberton, P. A.,
Kiefer, M. C.,
Travis, J.,
and Potempa, J.
(1998)
Biol. Chem.
379,
205-211[Medline]
[Order article via Infotrieve]
-
Rangarajan, M.,
Smith, S. J. M.,
and Curtis, M. A.
(1997)
Biochem. J.
323,
701-709
-
Curtis, M. A.,
Aduse-Opoku, J.,
Slaney, J. M.,
Rangarajan, M.,
Booth, V.,
Cridland, J.,
and Shepherd, P.
(1996)
Infect. Immun.
64,
2532-2539[Abstract]
-
Rangarajan, M.,
Aduse-Opoku, J.,
Slaney, J. M.,
Young, K. A.,
and Curtis, M. A.
(1997)
Mol. Microbiol.
23,
955-965[CrossRef][Medline]
[Order article via Infotrieve]
-
Berge, A.,
and Björck, L.
(1996)
J. Biol. Chem.
270,
9862-9867[Abstract/Free Full Text]
-
Pike, R. N.,
Potempa, J.,
McGraw, W.,
Coetzer, H. T.,
and Travis, J.
(1996)
J. Bacteriol.
178,
2876-2882[Abstract/Free Full Text]
-
Nishikata, M.,
and Yoshimura, F.
(1991)
Biochem. Biophys. Res. Commun.
178,
336-342[CrossRef][Medline]
[Order article via Infotrieve]
-
Chen, Z.,
Potempa, J.,
Polanowski, A.,
Renvert, S.,
Wikström, M.,
and Travis, J.
(1991)
Infect. Immun.
59,
2846-2850[Abstract/Free Full Text]
-
Wingrove, J.,
DiScipio, R. G.,
Chen, Z.,
Potempa, J.,
Travis, J.,
and Hugli, T. E.
(1992)
J. Biol. Chem.
267,
18902-18907[Abstract/Free Full Text]
-
Bleeg, H. S.,
and Polenik, P.
(1991)
FEMS Microbiol. Ecol.
85,
125-132[CrossRef]
-
Abrahamson, M.,
Wikström, M.,
Potempa, J.,
Renvert, S.,
and Hall, A.
(1997)
J. Clin. Pathol. Mol. Pathol.
50,
291-297[Abstract/Free Full Text]
-
Hinode, D.,
Nagata, S.,
Ichimiya, S.,
Hayashi, H.,
Morioka, M.,
and Nakamura, R.
(1992)
Arch. Oral Biol.
37,
859-861[CrossRef][Medline]
[Order article via Infotrieve]
-
Kaminishi, H.,
Cho, T.,
Itoh, T.,
Iwata, A.,
Kawasaki, K.,
Hagihara, Y.,
and Maeda, H.
(1993)
FEMS Microbiol. Lett.
114,
109-114[CrossRef][Medline]
[Order article via Infotrieve]
-
Imamura, T.,
Pike, R.,
Potempa, J.,
and Travis, J.
(1995)
J. Clin. Invest.
94,
361-367
-
Imamura, T.,
Potempa, J.,
Pike, R. N.,
Moore, J. N.,
Barton, M. H.,
and Travis, J.
(1995)
Infect. Immun.
63,
4877-4882[Abstract]
-
Curtis, M. A.,
Macey, M.,
Slaney, J. M.,
and Howells, G. L.
(1993)
FEMS Microbiol. Lett.
110,
167-174[CrossRef][Medline]
[Order article via Infotrieve]
-
Onoe, T.,
Hoover, C. I.,
Nakayama, K.,
Ideka, T.,
Nakamura, H.,
and Yoshimura, F.
(1995)
Microbiol. Pathol.
19,
351-364
-
Nakayama, K.,
Yoshimura, F.,
Kadowaki, T.,
and Yamamoto, K.
(1996)
J. Bacteriol.
178,
2818-2824[Abstract/Free Full Text]
-
Okamoto, K.,
Kadowaki, T.,
Nakayama, K.,
and Yamamoto, K.
(1996)
J. Biochem. (Tokyo)
120,
398-406[Abstract/Free Full Text]
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
L. G. Henry, L. Sandberg, K. Zhang, and H. M. Fletcher
DNA Repair of 8-Oxo-7,8-Dihydroguanine Lesions in Porphyromonas gingivalis
J. Bacteriol.,
December 15, 2008;
190(24):
7985 - 7993.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Potempa, J. Potempa, M. Okroj, K. Popadiak, S. Eick, K.-A. Nguyen, K. Riesbeck, and A. M. Blom
Binding of Complement Inhibitor C4b-Binding Protein Contributes to Serum Resistance of Porphyromonas gingivalis
J. Immunol.,
October 15, 2008;
181(8):
5537 - 5544.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Uehara, M. Naito, T. Imamura, J. Potempa, J. Travis, K. Nakayama, and H. Takada
Dual regulation of interleukin-8 production in human oral epithelial cells upon stimulation with gingipains from Porphyromonas gingivalis
J. Med. Microbiol.,
April 1, 2008;
57(4):
500 - 507.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Vanterpool, F. Roy, W. Zhan, S. M. Sheets, L. Sangberg, and H. M. Fletcher
VimA is part of the maturation pathway for the major gingipains of Porphyromonas gingivalis W83.
Microbiology,
November 1, 2006;
152(Pt 11):
3383 - 3389.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Roy, E. Vanterpool, and H. M. Fletcher
HtrA in Porphyromonas gingivalis can regulate growth and gingipain activity under stressful environmental conditions.
Microbiology,
November 1, 2006;
152(Pt 11):
3391 - 3398.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Sheets, J. Potempa, J. Travis, H. M. Fletcher, and C. A. Casiano
Gingipains from Porphyromonas gingivalis W83 Synergistically Disrupt Endothelial Cell Adhesion and Can Induce Caspase-Independent Apoptosis.
Infect. Immun.,
October 1, 2006;
74(10):
5667 - 5678.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. A. Seers, N. Slakeski, P. D. Veith, T. Nikolof, Y.-Y. Chen, S. G. Dashper, and E. C. Reynolds
The RgpB C-Terminal Domain Has a Role in Attachment of RgpB to the Outer Membrane and Belongs to a Novel C-Terminal-Domain Family Found in Porphyromonas gingivalis.
J. Bacteriol.,
September 1, 2006;
188(17):
6376 - 6386.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. W. Smalley, A. J. Birss, B. Szmigielski, and J. Potempa
The HA2 haemagglutinin domain of the lysine-specific gingipain (Kgp) of Porphyromonas gingivalis promotes {micro}-oxo bishaem formation from monomeric iron(III) protoporphyrin IX
Microbiology,
June 1, 2006;
152(6):
1839 - 1845.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Uehara, K. Muramoto, T. Imamura, K. Nakayama, J. Potempa, J. Travis, S. Sugawara, and H. Takada
Arginine-Specific Gingipains from Porphyromonas gingivalis Stimulate Production of Hepatocyte Growth Factor (Scatter Factor) through Protease-Activated Receptors in Human Gingival Fibroblasts in Culture
J. Immunol.,
November 1, 2005;
175(9):
6076 - 6084.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Vanterpool, F. Roy, and H. M. Fletcher
Inactivation of vimF, a Putative Glycosyltransferase Gene Downstream of vimE, Alters Glycosylation and Activation of the Gingipains in Porphyromonas gingivalis W83
Infect. Immun.,
July 1, 2005;
73(7):
3971 - 3982.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Tancharoen, K. P. Sarker, T. Imamura, K. K. Biswas, K. Matsushita, S. Tatsuyama, J. Travis, J. Potempa, M. Torii, and I. Maruyama
Neuropeptide Release from Dental Pulp Cells by RgpB via Proteinase-Activated Receptor-2 Signaling
J. Immunol.,
May 1, 2005;
174(9):
5796 - 5804.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Vanterpool, F. Roy, L. Sandberg, and H. M. Fletcher
Altered Gingipain Maturation in vimA- and vimE-Defective Isogenic Mutants of Porphyromonas gingivalis
Infect. Immun.,
March 1, 2005;
73(3):
1357 - 1366.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Mezyk-Kopec, M. Bzowska, J. Potempa, M. Bzowska, N. Jura, A. Sroka, R. A. Black, and J. Bereta
Inactivation of Membrane Tumor Necrosis Factor Alpha by Gingipains from Porphyromonas gingivalis
Infect. Immun.,
March 1, 2005;
73(3):
1506 - 1514.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Sheets, J. Potempa, J. Travis, C. A. Casiano, and H. M. Fletcher
Gingipains from Porphyromonas gingivalis W83 Induce Cell Adhesion Molecule Cleavage and Apoptosis in Endothelial Cells
Infect. Immun.,
March 1, 2005;
73(3):
1543 - 1552.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Kawalec, J. Potempa, J. L. Moon, J. Travis, and B. E. Murray
Molecular Diversity of a Putative Virulence Factor: Purification and Characterization of Isoforms of an Extracellular Serine Glutamyl Endopeptidase of Enterococcus faecalis with Different Enzymatic Activities
J. Bacteriol.,
January 1, 2005;
187(1):
266 - 275.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Vanterpool, F. Roy, and H. M. Fletcher
The vimE Gene Downstream of vimA Is Independently Expressed and Is Involved in Modulating Proteolytic Activity in Porphyromonas gingivalis W83
Infect. Immun.,
October 1, 2004;
72(10):
5555 - 5564.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K.-A. Nguyen, A. A. DeCarlo, M. Paramaesvaran, C. A. Collyer, D. B. Langley, and N. Hunter
Humoral Responses to Porphyromonas gingivalis Gingipain Adhesin Domains in Subjects with Chronic Periodontitis
Infect. Immun.,
March 1, 2004;
72(3):
1374 - 1382.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Mikolajczyk, K. M. Boatright, H. R. Stennicke, T. Nazif, J. Potempa, M. Bogyo, and G. S. Salvesen
Sequential Autolytic Processing Activates the Zymogen of Arg-gingipain
J. Biol. Chem.,
March 14, 2003;
278(12):
10458 - 10464.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Katz, Q.-B. Yang, P. Zhang, J. Potempa, J. Travis, S. M. Michalek, and D. F. Balkovetz
Hydrolysis of Epithelial Junctional Proteins by Porphyromonas gingivalis Gingipains
Infect. Immun.,
May 1, 2002;
70(5):
2512 - 2518.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. P. McRedmond, D. J. Fitzgerald ;, R. N. Pike, A. Lourbakos, J. Travis, and J. Potempa
A growing set of platelet-activating bacterial proteins
Blood,
January 1, 2002;
99(1):
387 - 388.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. M. O'Brien-Simpson, R. A. Paolini, B. Hoffmann, N. Slakeski, S. G. Dashper, and E. C. Reynolds
Role of RgpA, RgpB, and Kgp Proteinases in Virulence of Porphyromonas gingivalis W50 in a Murine Lesion Model
Infect. Immun.,
December 1, 2001;
69(12):
7527 - 7534.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. C. Gibson III and C. A. Genco
Prevention of Porphyromonas gingivalis-Induced Oral Bone Loss following Immunization with Gingipain R1
Infect. Immun.,
December 1, 2001;
69(12):
7959 - 7963.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Imamura, K. Matsushita, J. Travis, and J. Potempa
Inhibition of Trypsin-Like Cysteine Proteinases (Gingipains) from Porphyromonas gingivalis by Tetracycline and Its Analogues
Antimicrob. Agents Chemother.,
October 1, 2001;
45(10):
2871 - 2876.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
T. Olczak, D. W. Dixon, and C. A. Genco
Binding Specificity of the Porphyromonas gingivalis Heme and Hemoglobin Receptor HmuR, Gingipain K, and Gingipain R1 for Heme, Porphyrins, and Metalloporphyrins
J. Bacteriol.,
October 1, 2001;
183(19):
5599 - 5608.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Sroka, M. Sztukowska, J. Potempa, J. Travis, and C. A. Genco
Degradation of Host Heme Proteins by Lysine- and Arginine-Specific Cysteine Proteinases (Gingipains) of Porphyromonas gingivalis
J. Bacteriol.,
October 1, 2001;
183(19):
5609 - 5616.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. L. W. Yun, A. A. Decarlo, C. Collyer, and N. Hunter
Hydrolysis of Interleukin-12 by Porphyromonas gingivalis Major Cysteine Proteinases May Affect Local Gamma Interferon Accumulation and the Th1 or Th2 T-Cell Phenotype in Periodontitis
Infect. Immun.,
September 1, 2001;
69(9):
5650 - 5660.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Lourbakos, J. Potempa, J. Travis, M. R. D'Andrea, P. Andrade-Gordon, R. Santulli, E. J. Mackie, and R. N. Pike
Arginine-Specific Protease from Porphyromonas gingivalis Activates Protease-Activated Receptors on Human Oral Epithelial Cells and Induces Interleukin-6 Secretion
Infect. Immun.,
August 1, 2001;
69(8):
5121 - 5130.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Oido-Mori, R. Rezzonico, P.-L. Wang, Y. Kowashi, J.-M. Dayer, P. C. Baehni, and C. Chizzolini
Porphyromonas gingivalis Gingipain-R Enhances Interleukin-8 but Decreases Gamma Interferon-Inducible Protein 10 Production by Human Gingival Fibroblasts in Response to T-Cell Contact
Infect. Immun.,
July 1, 2001;
69(7):
4493 - 4501.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Lourbakos, Y. Yuan, A. L. Jenkins, J. Travis, P. Andrade-Gordon, R. Santulli, J. Potempa, and R. N. Pike
Activation of protease-activated receptors by gingipains from Porphyromonas gingivalis leads to platelet aggregation: a new trait in microbial pathogenicity
Blood,
June 15, 2001;
97(12):
3790 - 3797.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Gusman, J. Travis, E. J. Helmerhorst, J. Potempa, R. F. Troxler, and F. G. Oppenheim
Salivary Histatin 5 Is an Inhibitor of Both Host and Bacterial Enzymes Implicated in Periodontal Disease
Infect. Immun.,
March 1, 2001;
69(3):
1402 - 1408.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Rice, R. Peralta, D. Bast, J. de Azavedo, and M. J. McGavin
Description of Staphylococcus Serine Protease (ssp) Operon in Staphylococcus aureus and Nonpolar Inactivation of sspA-Encoded Serine Protease
Infect. Immun.,
January 1, 2001;
69(1):
159 - 169.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Abaibou, Z. Chen, G. J. Olango, Y. Liu, J. Edwards, and H. M. Fletcher
vimA Gene Downstream of recA Is Involved in Virulence Modulation in Porphyromonas gingivalis W83
Infect. Immun.,
January 1, 2001;
69(1):
325 - 335.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M.A. Curtis, J. Aduse-Opoku, and M. Rangarajan
Cysteine Proteases of Porphyromonas Gingivalis
Critical Reviews in Oral Biology & Medicine,
January 1, 2001;
12(3):
192 - 216.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Curtis, A. Thickett, J. M. Slaney, M. Rangarajan, J. Aduse-Opoku, P. Shepherd, N. Paramonov, and E. F. Hounsell
Variable Carbohydrate Modifications to the Catalytic Chains of the RgpA and RgpB Proteases of Porphyromonas gingivalis W50
Infect. Immun.,
August 1, 1999;
67(8):
3816 - 3823.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. L. W. Yun, A. A. DeCarlo, and N. Hunter
Modulation of Major Histocompatibility Complex Protein Expression by Human Gamma Interferon Mediated by Cysteine Proteinase-Adhesin Polyproteins of Porphyromonas gingivalis
Infect. Immun.,
June 1, 1999;
67(6):
2986 - 2995.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Nelson, J. Potempa, T. Kordula, and J. Travis
Purification and Characterization of a Novel Cysteine Proteinase (Periodontain) from Porphyromonas gingivalis. EVIDENCE FOR A ROLE IN THE INACTIVATION OF HUMAN alpha 1-PROTEINASE INHIBITOR
J. Biol. Chem.,
April 30, 1999;
274(18):
12245 - 12251.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Imamura, A. Banbula, P. J. B. Pereira, J. Travis, and J. Potempa
Activation of Human Prothrombin by Arginine-specific Cysteine Proteinases (Gingipains R) from Porphyromonas gingivalis*
J. Biol. Chem.,
May 25, 2001;
276(22):
18984 - 18991.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|